Suppr超能文献

多发性硬化症诊断与治疗挑战的细胞和分子证据

Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges.

作者信息

Khan Zuber, Gupta Ghanshyam Das, Mehan Sidharth

机构信息

Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy, IK Gujral Punjab Technical University, Jalandhar 144603, India.

Department of Pharmaceutics, ISF College of Pharmacy, IK Gujral Punjab Technical University, Jalandhar 144603, India.

出版信息

J Clin Med. 2023 Jun 26;12(13):4274. doi: 10.3390/jcm12134274.

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disease that impacts the central nervous system and can result in disability. Although the prevalence of MS has increased in India, diagnosis and treatment continue to be difficult due to several factors. The present study examines the difficulties in detecting and treating multiple sclerosis in India. A lack of MS knowledge among healthcare professionals and the general public, which delays diagnosis and treatment, is one of the significant issues. Inadequate numbers of neurologists and professionals with knowledge of MS management also exacerbate the situation. In addition, MS medications are expensive and not covered by insurance, making them inaccessible to most patients. Due to the absence of established treatment protocols and standards for MS care, India's treatment techniques vary. In addition, India's population diversity poses unique challenges regarding genetic variations, cellular and molecular abnormalities, and the potential for differing treatment responses. MS is more difficult to accurately diagnose and monitor due to a lack of specialized medical supplies and diagnostic instruments. Improved awareness and education among healthcare professionals and the general public, as well as the development of standardized treatment regimens and increased investment in MS research and infrastructure, are required to address these issues. By addressing these issues, it is anticipated that MS diagnosis and treatment in India will improve, leading to better outcomes for those affected by this chronic condition.

摘要

多发性硬化症(MS)是一种影响中枢神经系统并可能导致残疾的慢性自身免疫性疾病。尽管印度多发性硬化症的患病率有所上升,但由于多种因素,诊断和治疗仍然困难重重。本研究探讨了印度在多发性硬化症检测和治疗方面存在的困难。医疗保健专业人员和普通公众对多发性硬化症缺乏了解,这会延误诊断和治疗,是一个重大问题。神经科医生以及掌握多发性硬化症管理知识的专业人员数量不足也使情况更加恶化。此外,多发性硬化症药物价格昂贵且不在保险范围内,大多数患者无法获得。由于缺乏既定的多发性硬化症护理治疗方案和标准,印度的治疗技术各不相同。此外,印度的人口多样性在基因变异、细胞和分子异常以及不同治疗反应的可能性方面带来了独特的挑战。由于缺乏专业医疗用品和诊断仪器,多发性硬化症更难以准确诊断和监测。需要提高医疗保健专业人员和普通公众的认识并加强教育,制定标准化治疗方案,增加对多发性硬化症研究和基础设施的投资,以解决这些问题。通过解决这些问题,预计印度的多发性硬化症诊断和治疗将得到改善,从而为受这种慢性病影响的人带来更好的结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad2a/10342392/65e2393cb53a/jcm-12-04274-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验